Prevent efficacy pool: this contract supports the prevent cancer preclinical drug development program, which provides a structured approach to drug and vaccine development, from discovery to the…
Ended Awarded Last action
- Contract number
- 75N91019D00020
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 15 $12,738,350 obligated
Award facts
- Opportunity
-
- PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing Pre-Solicitation · N01CN7701918 · Posted Apr 19, 2018
- PREVENT Cancer Preclinical Drug Development Program Award Notice · Posted May 7, 2018
- Combined order value
- $12,738,350 Current and potential, with all options
- Last date to order 100% complete
- IDV ceiling 17% used
- $74,995,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Cancer Institute awarded an Indefinite Delivery/Indefinite Quantity contract to University Of Oklahoma (Board of Regents of the University of Oklahoma Health Sciences Center) on January 24, 2019, with a ceiling of $74,995,000 and an ultimate completion date of January 24, 2024. This is one of multiple awards under the PREVENT Cancer Preclinical Drug Development Program's Efficacy Pool, which procures services for preclinical efficacy evaluation and intermediate endpoint biomarkers in support of cancer prevention drug and vaccine development.
Work is performed in Oklahoma City, Oklahoma. The originating solicitation sought proposals for preclinical efficacy and biomarker evaluation services supporting structured drug and vaccine development from discovery through clinical advancement, with up to 20 IDIQ contracts awarded across three service pools and anticipated task orders requiring testing on 50–100 agents annually across 50–150 studies.
The contract term runs January 24, 2019 through January 24, 2024. Primary NAICS codes are 541715 and 541712, with PSC code R408.
Task order activity under this IDIQ includes delivery orders for colorectal cancer prevention using TPST-1495 in rat models ($1.14 million, awarded September 2023, completion September 2026); chemoprevention with mitochondria-targeted honokiol in lung cancer mouse models ($1.20 million, awarded September 2022); lung adenocarcinoma prevention using ONC201 ($982,258, awarded September 2022); bladder cancer chemoprevention using apalutamide ($1.44 million, awarded August 2022); and familial adenomatous polyposis-associated colorectal cancer prevention using RLON protease ($139,980, awarded June 2022). Earlier task orders funded vaccine development for triple-negative breast cancer, ovarian carcinoma antigen evaluation, pancreatic cancer prevention via KRAS vaccine, and lung cancer immunoprevention approaches. Houston Methodist Hospital and Medical College of Wisconsin serve as subcontractors on select task orders.
Description
Prevent efficacy pool: this contract supports the prevent cancer preclinical drug development program, which provides a structured approach to drug and vaccine development, from discovery to the clinic. This contract is part of a multiple-award indefinite delivery indefinite quantity (IDIQ) pool to procure services related to preclinical efficacy and intermediate endpoint biomarkers, which is also referred to as the "efficacy pool."
Task orders
Show all 15
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Additional Work (new agreement, FAR part 6 applies) | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| The Methodist Hospital | $5,714 | |
| The Methodist Hospital | $3,800 |
Quick answers
Who was awarded contract 75N91019D00020?
75N91019D00020 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on January 24, 2019.
How much is contract 75N91019D00020 worth?
Orders under 75N91019D00020 have obligated $12,738,350. 75N91019D00020's own ceiling is $74,995,000.
How many orders have been placed under contract 75N91019D00020?
15 orders have been placed under 75N91019D00020, the latest on September 11, 2023.
Who can order from contract 75N91019D00020?
75N91019D00020 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N91019D00020 part of a contract vehicle?
Yes. 75N91019D00020 is part of PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91019D00020 competed?
The extent of competition for 75N91019D00020 was full and open competition. The government received 9 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV